Serum monoclonal immunoglobulin (Ig) is the main diagnostic factor for patients with multiple myeloma (MM), however its prognostic potential remains unclear. On a large MM patient cohort (n = 4146), we observe no correlation between serum Ig levels and patient survival, while amount of intracellular Ig has a strong predictive effect. Focused CRISPR screen, transcriptional and proteomic analysis identify deubiquitinase OTUD1 as a critical mediator of Ig synthesis, proteasome inhibitor sensitivity and tumor burden in MM. Mechanistically, OTUD1 deubiquitinates peroxiredoxin 4 (PRDX4), protecting it from endoplasmic reticulum (ER)-associated degradation. In turn, PRDX4 facilitates Ig production which coincides with the accumulation of unfolded proteins and higher ER stress. The elevated load on proteasome ultimately potentiates myeloma response to proteasome inhibitors providing a window for a rational therapy. Collectively, our findings support the significance of the Ig production machinery as a biomarker and target in the combinatory treatment of MM patients.

Department of Hematooncology Faculty of Medicine University of Ostrava Ostrava Syllabova 19 703 00 Czech Republic

Department of Hematooncology University Hospital Ostrava Ostrava 17 listopadu 1790 5 708 00 Czech Republic

Faculty of Science University of Ostrava Ostrava 30 dubna 22 701 03 Czech Republic

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. PubMed

Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 2017;14:417–433. PubMed PMC

Facon T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582–1596. PubMed

Meister S, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783–1792. PubMed

Chim CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252–262. PubMed PMC

Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. PubMed

Schaefer EW, et al. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. Cancer. 2010;116:640–646. PubMed PMC

Yan X, et al. Early M‐protein dynamics predicts progression‐free survival in patients with relapsed/refractory multiple myeloma. Clin. Transl. Sci. 2020;13:1345–1354. PubMed PMC

Jackson D, Elsawa S. Factors regulating immunoglobulin production by normal and disease-associated plasma cells. Biomolecules. 2015;5:20–40. PubMed PMC

Christianson JC, Ye Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 2014;21:325–335. PubMed PMC

Vincenz L, Jäger R, O’Dwyer M, Samali A. Endoplasmic reticulum stress and the unfolded protein response: targeting the achilles heel of multiple myeloma. Mol. Cancer Ther. 2013;12:831–843. PubMed

Nikesitch N, Lee JM, Ling S, Roberts TL. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin. Transl. Immunol. 2018;7:e1007. PubMed PMC

Aronson LI, Davies FE. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica. 2012;97:1119–1130. PubMed PMC

Cenci S, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25:1104–1113. PubMed PMC

Auner HW, Beham-Schmid C, Dillon N, Sabbattini P. The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood. 2010;116:3445–3455. PubMed

Obeng EA, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–4916. PubMed PMC

Cenci S, et al. Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J. Leukoc. Biol. 2012;92:921–931. PubMed

Leung-Hagesteijn C, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289–304. PubMed PMC

Acosta-Alvear D, et al. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. Elife. 2015;4:e08153. PubMed PMC

Hofman IJF, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia. 2017;31:1706–1714. PubMed PMC

De Veas Silva JLG, et al. Prognostic value of serum free light chains measurements in multiple myeloma patients. PLoS ONE. 2016;11:e0166841. PubMed PMC

Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–144. PubMed

Rafae A, Malik MN, Abu Zar M, Durer S, Durer C. An overview of light chain multiple myeloma: clinical characteristics and rarities, management strategies, and disease monitoring. Cureus. 2018;10:e3148. PubMed PMC

Low MSY, et al. IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis. Cell Rep. 2019;29:2634–2645.e5. PubMed

Kassambara A, et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput. Biol. 2015;11:e1004077. PubMed PMC

Bianchi G, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113:3040–3049. PubMed

Cho KF, et al. Proximity labeling in mammalian cells with TurboID and split-TurboID. Nat. Protoc. 2020;15:3971–3999. PubMed

Hast BE, et al. Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination. Cancer Res. 2013;73:2199–2210. PubMed PMC

Morrow ME, et al. Active site alanine mutations convert deubiquitinases into high‐affinity ubiquitin‐binding proteins. EMBO Rep. 2018;19:e45680. PubMed PMC

Zito E, et al. Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin. Mol. Cell. 2010;40:787–797. PubMed PMC

Feige MJ, Hagn F, Esser J, Kessler H, Buchner J. Influence of the internal disulfide bridge on the folding pathway of the CL antibody domain. J. Mol. Biol. 2007;365:1232–1244. PubMed

Demasi APD, et al. Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation. Virchows Arch. 2013;463:47–55. PubMed

Yao F, et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. Nat. Commun. 2018;9:1–16. PubMed PMC

Wu X, Rapoport TA. Mechanistic insights into ER-associated protein degradation. Curr. Opin. Cell Biol. 2018;53:22. PubMed PMC

Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat. Cell Biol. 2005;7:766–772. PubMed

Bernardi KM, Williams JM, Inoue T, Schultz A, Tsai B. A deubiquitinase negatively regulates retro-translocation of nonubiquitinated substrates. Mol. Biol. Cell. 2013;24:3545–3556. PubMed PMC

Elko EA, et al. Oxidation of peroxiredoxin-4 induces oligomerization and promotes interaction with proteins governing protein folding and endoplasmic reticulum stress. J. Biol. Chem. 2021;296:100665. PubMed PMC

Garshott DM, Sundaramoorthy E, Leonard M, Bennett EJ. Distinct regulatory ribosomal ubiquitylation events are reversible and hierarchically organized. Elife. 2017;9:e54023. PubMed PMC

Carneiro AP, et al. A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumors. Br. J. Cancer. 2014;111:551–558. PubMed PMC

Qin X-Q, et al. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv. 2019;3:751–760. PubMed PMC

Zhang Z, et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat. Commun. 2017;8:2116. PubMed PMC

Deng, J., Hou, G., Fang, Z., Liu, J. & Lv, X. Distinct expression and prognostic value of OTU domain-containing proteins in non-small-cell lung cancer. Oncol. Lett.10.3892/ol.2019.10883 (2019). PubMed PMC

Thies MJW, et al. Folding and oxidation of the antibody domain CH3. J. Mol. Biol. 2002;319:1267–1277. PubMed

Bertolotti M, et al. B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses. Antioxid. Redox Signal. 2010;13:1133–1144. PubMed

Holtkamp W, et al. Cotranslational protein folding on the ribosome monitored in real time. Science. 2015;350:1104–1107. PubMed

Buhr F, et al. Synonymous codons direct cotranslational folding toward different protein conformations. Mol. Cell. 2016;61:341–351. PubMed PMC

Stein KC, Frydman J. The stop-and-go traffic regulating protein biogenesis: How translation kinetics controls proteostasis. J. Biol. Chem. 2019;294:2076–2084. PubMed PMC

Liu K, Maciuba K, Kaiser CM. The ribosome cooperates with a chaperone to guide multi-domain protein folding. Mol. Cell. 2019;74:310–319.e7. PubMed PMC

Mitra AK, et al. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. Blood Cancer J. 2020;10:78. PubMed PMC

Robinson RM, et al. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019;33:1011–1022. PubMed PMC

Aiken CT, Kaake RM, Wang X, Huang L. Oxidative stress-mediated regulation of proteasome complexes. Mol. Cell. Proteom. 2011;10:006924. PubMed PMC

Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteom. 2014;13:2513–2526. PubMed PMC

Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome- wide protein quantification. Nat. Biotechnol. 2008;26:1367–1372. PubMed

Tyanova S, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods. 2016;13:731–740. PubMed

Sowa M, Bennett E, Gygi S, Harper J. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138:389–403. PubMed PMC

Tropea J, Cherry S, Waugh D. Expression and purification of soluble His(6)-tagged TEV protease. Methods Mol. Biol. 2009;498:297–307. PubMed

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors